Sp1072
IMPLEMENTATION OF SCREENING FOR BARRETT'S ESOPHAGUS - WHAT WILL IT TAKE?
Date
May 21, 2024
Presenter
Tracks
Related Products
BEYOND TFF3: IDENTIFYING NON-ENDOSCOPIC DNA METHYLATION BIOMARKERS FOR IMPROVED DIAGNOSIS OF BARRETT'S ESOPHAGUS
Esophageal adenocarcinoma (EAC) is increasingly prevalent, with most cases detected in advanced stages and exhibiting less than a 20% 5-year overall survival rate. Since this cancer develops from Barrett's Esophagus (BE) through dysplastic stages, there is a clear opportunity for early diagnosis…
A PROSPECTIVE, MULTI-INSTITUTIONAL STUDY REVEALS THE COMBINATION OF RNA ANALYSIS WITH DNA-BASED NEXT-GENERATION SEQUENCING (NGS) IMPROVES THE PREOPERATIVE CLASSIFICATION OF PANCREATIC CYSTS AND IDENTIFICATION OF ADVANCED NEOPLASIA
BACKGROUND: As outlined by the Kyoto guidelines, targeted DNA-based NGS of pancreatic cyst fluid (PCF) is an important adjunct to the evaluation of pancreatic cyst patients…
NEW SCREENING METHODS: WILL IT HAPPEN?
A variety of new developments in the realms of screening and surveillance of Barrett's esophagus have occurred in recent years. This session will focus on the current evidence base for risk assessment algorithms to enhance screening uptake, new screening tools and obstacles to implementation…
